Our philosophy

Topical Innovations builds forth on a long term commitment of its founders to develop and test compounded analgesic creams in various patient populations suffering from neuropathic pain.  We developed a unique system to directly test prototypes of topical formulations directly in the clinic, and use the feedback of patients to optimize those formulations. We described this method to select responders recently in peer reviewed journals (1,2).

Heterogeneity of response to analgesic therapy is a well-recognized clinical phenomenon. A great percentage of patients suffering from neuropathic pain sadly enough appear to be non- or partial responders to therapy. Most likely this is due to a mismatch between therapy and the pathogenesis of the neuropathic pain in the individual case.

Based on this insight we explored and developed a special ex-juvantibus approach linking diagnosis and therapy-response on an individual patient base: the backbone of an individualized medicine. We feel this ex-juvantibus approach helps to identify a contribution of a peripheral neurogenic inflammation or small fibre neuropathic component in neuropathic pain and subsequently helps to better target the patient population for different analgesic therapies.

Our experience thus led to a new approach to create an optimal fit between the pathogenesis of various neuropathic pain syndromes and its therapy. We could then create a continuous stream of new formulations of various analgesic drugs and test those directly, as compounded creams, in the target populations. Based on our selection of certain base-creams we could create topicals with a quick action of onset: between 10-30 minutes. Due to this unique combination and interaction between bench research and direct evaluation of the results in patients we could screen many different analgesics and concentrations of analgesics and pick out the best.

By using an innovative test-design (blinded enrichment cross-over testing) (1,2) we also could, together with the patient, quickly test the pain relief of various formulations, compare and select the best. This is the reason why we could optimize our formulations in a fast turn-around time and test efficacy and safety for each patient individually.

Based on these direct hands-on experiences Topical Innovations could optimize its innovative formulations and created a patent strategy around one key compound as a stand-alone and in combination with a multitude of various analgesics.

Topical Innovations is currently looking for pharmaceutical partners to take over clinical drug development and marketing of its key development creams.

  1. Keppel Hesselink JM, Kopsky DJ. Burning pain in small fibre neuropathy treated with topical phenytoin: rationale and case presentations. J Clin Anesth Pain Med. 2017; 1(1): 6. (PDF)
  2. Keppel Hesselink JM, Kopsky DJ. Topical phenytoin in neuralgic pain, peripheral modulation of central sensitization: two case reports. J Pain Relief  2017; 6(2): 284. (PDF)